mRNA：各种药品和世界市场

全球 mRNA 药物市场规模预计将从 2023 年的 330 亿美元下降到年终的210 亿美元，预测期内复合年增长率为 -8.6%。

新冠疫苗部门预计将从 2023 年的 330 亿美元下降到 2028 年的 169 亿美元，复合年增长率为-12.5%。同时，非新冠病毒药物和疫苗部门预计到 2025 年将成长至 5.6 亿美元，到 2028 年将成长至 41 亿美元，预测期内复合年增长率为 94.7%。

本报告调查了全球mRNA 药物市场，并按各个细分市场和地区提供了市场和药物的概述和背景、市场影响因素和市场机会、目标疾病和病症、市场规模趋势和预测的分析。它总结了详细资讯主要企业的技术和专利趋势、竞争形势和概况分析。

目录

第一章简介

第 2 章摘要/亮点

• 市场展望
• 市场摘要

第三章市场概况

• RNA医学的演变
• RNA医学的历史
• RNA药物及其类型的开发
• DNA药物与RNA药物
• RNA药物的临床需求
• 患病人数增加和经济负担增加
• 传统药物的局限性
• 生技药品的治疗局限性
• 慢性病管理不善
• 罕见疾病治疗有限
• RNA医学
• 反义寡核苷酸 (ASO) 作为药物
• 小干扰 RNA (siRNA) 作为药物
• miRNA作为药物
• 适体作为药物
• mRNA作为药物
• 製造基于 RNA 的生物製药
• 层析法精製程式
• 提供RNA药品
• 聚合物键结/化学改性
• 封装
• 脂质奈米粒子
• 高分子奈米材料
• 二氧化硅奈米粒子
• 碳和金奈米材料
• GalNAc
• 设施和医院的 RNA 药物
• 法规对 RNA 药品市场的影响
• COVID-19 的影响

第四章市场动态

• 市场动态
• 促进因素
• 抑制因素
• 机会

第五章 目标疾病与病症

• mRNA 药物常见疾病和病症概述
• 癌症
• 感染疾病
• 循环系统疾病
• 文明病
• 呼吸系统疾病
• 肌肉骨骼疾病
• 胃肠道疾病
• 泌尿系统疾病
• 肾臟疾病
• 免疫疾病
• 神经系统疾病
• 罕见疾病
• 其他疾病
• 吸烟与相关疾病
• 感染疾病：COVID-19 大流行和 mRNA 药物
• 慢性病：扩大 mRNA 药物的视野
• 罕见疾病中未满足的需求：mRNA 药物
• 老化、性别和疾病发生
• 世界人口统计
• 美国人口统计
• 欧洲人口统计
• 日本人口统计

第六章 研发管线和临床试验分析

• mRNA疫苗
• mRNA医学
• 临床试验分析

第七章市场区隔：依产品

• mRNA COVID 疫苗的作用机制
• 三种最先进的mRNA疫苗

第八章市场细分：按地区

• 北美洲
• 加拿大
• 欧洲
• 亚太地区
• 日本
• 韩国
• 中国
• 印度
• 澳洲
• 其他地区

第九章 新技术与新进展

• 概述
• 奈米粒子
• 修饰的mRNA
• mRNA自动合成套件
• 生物平台

第10章 专利分析

• 专利分析
• mRNA应用发表

第十一章 併购与资金筹措

第十二章竞争资讯

第十三章 公司简介

• ARCTUR US THERAPEUTICS INC.
• BIONTECH SE
• CUREVAC NV
• GENNOVA BIOPHARMACEUTICALS LTD.
• MERCK KGAA
• MODERNA INC.
• NUTCRACKER THERAPEUTICS
• OMEGA THERAPEUTICS INC.
• STRAND THERAPEUTICS
• VAXESS TECHNOLOGIES INC.

Highlights:

The global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a compound annual growth rate (CAGR) of -8.6% during the forecast period of 2023-2028.

The COVID vaccines segment of the mRNA therapeutics market is expected to decline from $33 billion in 2023 to $16.9 billion by 2028, at a CAGR of -12.5% during the forecast period of 2023-2028.

The non-COVID therapeutics and vaccines segment of the mRNA therapeutics market is expected to grow from $560 million in 2025 to $4.1 billion by 2028, at a CAGR of 94.7% during the forecast period of 2023-2028.

Report Scope:

This report focuses on the mRNA therapeutics market. This reports include the types of mRNA and their application in therapy. Also, the report focuses on the patent analysis and clinical trial analysis of mRNA. The report also portrays the trends and dynamics affecting the market during the study period. The study covers market projections through 2028 and profiles major market players.

By geography, the market is segregated into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The market is estimated through 2028.

BCC Research also summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022 and identifies the trends in this activity.

Report Includes:

• 37 data tables and 27 additional tables
• An overview of the global market related to mRNA therapeutics
• In-depth analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market and revenue growth prospects specific to mRNA therapeutics, accompanied by a market share analysis by therapeutic type and geographical region
• Coverage of the pandemic threats, therapeutic developments, and new technologies in the market
• Discussion of the advantages of mRNA over protein- and DNA-based delivery systems, demographic and economic trends, and outlook for the mRNA therapeutics market
• Information on prophylactic vaccines, vaccine discovery and development, and R&D activities
• Analysis of the various therapeutics as well as promising vaccines intended for the prevention and treatment of chronic and infectious diseases
• Assessment of regulatory structure, pricing and reimbursement scenarios, the pipeline for new molecules and therapeutics
• Market share analysis of the key companies and mergers & acquisitions, joint ventures, collaborations, and partnerships
• Profiles of leading market participants

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Evolution of RNA Therapeutics
• History of RNA Therapeutics
• Development of RNA Therapeutics and Types
• DNA Therapeutics vs. RNA Therapeutics
• Clinical Need for RNA Therapeutics
• Increasing Disease Population and Economic Burden
• Limitations of Traditional Therapeutics
• Therapeutic Limitations of Biologics
• Poor Management of Chronic Diseases
• Limited Treatment for Rare Diseases
• RNA Therapeutics
• Antisense Oligonucleotide (ASO) as Therapeutics
• Small Interfering RNA (siRNA) as Therapeutics
• miRNA as Therapeutics
• Aptamers as Therapeutics
• mRNA as Therapeutics
• Manufacturing RNA-Based Biopharmaceuticals
• Chromatographic Purification Steps
• Delivery of RNA Therapeutics
• Polymer Conjugation/Chemical Modification
• Encapsulation
• Lipid-Based Nanoparticles
• Polymer Nanomaterials
• Silica Nanoparticles
• Carbon and Gold Nanomaterials
• GalNAc
• Institution and Hospital-Based RNA Therapeutics
• Regulatory Influence on the Market for RNA Therapeutics
• Impact of COVID-19

Chapter 4 Market Dynamics

• Market Dynamics
• Drivers
• Restraints
• Opportunities

Chapter 5 Target Disease and Disorders

• Overview of Common Diseases and Disorders for mRNA Therapeutics
• Cancer
• Infectious Diseases
• Cardiovascular Disease
• Lifestyle Disorders
• Respiratory Disorders
• Musculoskeletal Disorders
• Gastrointestinal Disorders
• Urology Disorders
• Nephrology Disorders
• Immune Disorders
• Neurological Disorders
• Rare Diseases
• Other Disorders
• Tobacco Smoking and Associated Diseases
• Infectious Diseases: COVID-19 Pandemic and mRNA Therapeutics
• Chronic Diseases: Expanding Horizon for mRNA Therapeutics
• Unmet Needs of Rare Diseases: mRNA Therapeutics
• Aging, Gender and Onset of Diseases
• Global Demographics
• U.S. Demographics
• European Demographics
• Japanese Demographics

Chapter 6 Pipeline and Clinical Trial Analysis

• mRNA Vaccines
• mRNA Therapeutics
• Clinical Trial Analysis

Chapter 7 Market Breakdown by Product

• Mechanism of Action of mRNA COVID Vaccines
• Three Most-Advanced mRNA Vaccines

Chapter 8 Market Breakdown by Region

• North America
• Canada
• Europe
• Asia-Pacific
• Japan
• South Korea
• China
• India
• Australia
• RoW

Chapter 9 Emerging Technologies and Developments

• Overview
• Nanoparticles
• Modified mRNA
• Automated mRNA Synthesis Kits
• Bio Platforms

Chapter 10 Patent Analysis

• Patent Analysis
• mRNA Publication

Chapter 11 Outlook for Mergers & Acquisitions, and Venture Funding

Chapter 12 Competitive Intelligence

Chapter 13 Company Profiles

• ARCTUR U.S. THERAPEUTICS INC.
• BIONTECH SE
• CUREVAC N.V.
• GENNOVA BIOPHARMACEUTICALS LTD.
• MERCK KGAA
• MODERNA INC.
• NUTCRACKER THERAPEUTICS
• OMEGA THERAPEUTICS INC.
• STRAND THERAPEUTICS
• VAXESS TECHNOLOGIES INC.

List of Tables

• Summary Table : Global Market for mRNA Therapeutics, by Type, Through 2028
• Table 1 : COVID-19: Total Cases and Deaths, by Select Country, 2023
• Table 2 : Pandemics of the 21st Century
• Table 3 : Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
• Table 4 : Global Epidemiology of Colorectal Cancer Cases, by Region, Through 2030
• Table 5 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
• Table 6 : Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
• Table 7 : Case Fatality Rate, Global Viral Outbreaks, 2020
• Table 8 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
• Table 9 : Global Prevalence of Angina Pectoris and Stroke (Survivors), Through 2030
• Table 10 : Global Prevalence of CHF and Stroke, Through 2030
• Table 11 : Structural Heart Disease Management Through Medications
• Table 12 : BMI Categories Based on Increasing Health Risks
• Table 13 : Trends in Obesity Composition of the Global Population, Through 2025
• Table 14 : Obesity and Severe Obesity vs. General Population in the U.S., Through 2025
• Table 15 : Global Distribution of Diabetes, by Type
• Table 16 : Global Prevalence of Diabetes, by Type, Through 2040
• Table 17 : Global Prevalence of Key Symptomatic Musculoskeletal Disorders, Through 2025
• Table 18 : Global Deaths, by Type of Musculoskeletal Disorder, Through 2030
• Table 19 : Global Deaths from Digestive Diseases, by Region, Through 2025
• Table 20 : Global Distribution of Mortality, by Chronic Disease Type, 2019
• Table 21 : Global Distribution of DALYs, by Chronic Disease Type, 2019
• Table 22 : Estimated World Population and Annual Growth, by Age Group, Through 2030
• Table 23 : Total Global Population, by Select Country/Region, Through 2030
• Table 24 : U.S. Population Projections and Estimates, by Age Group, Through 2030
• Table 25 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
• Table 26 : European Population Estimates and Projections, by Age Group, Through 2030
• Table 27 : Japanese Population Estimates and Projections, by Age Group, Through 2030
• Table 28 : Clinical Trials on mRNA Vaccine Candidates, 2023
• Table 29 : Clinical Trials on mRNA Vaccine Candidates for Cancer Treatments, as of 2023
• Table 30 : Clinical Trials on mRNA Therapeutic Application
• Table 31 : Properties of BNT162b2 Vaccine
• Table 32 : Properties of mRNA-1273 Vaccine
• Table 33 : Properties of CVnCoV Vaccine
• Table 34 : Global Market for COVID Vaccines, by Region, Through 2028
• Table 35 : Global Market for Non-COVID mRNA Therapeutics, by Region, Through 2028
• Table 36 : Global Market for mRNA Therapeutics, by Region, Through 2028
• Table 37 : North American Market for mRNA Therapeutics, by Type, Through 2028
• Table 38 : European Market for mRNA Therapeutics, by Type, Through 2028
• Table 39 : Asia-Pacific Market for mRNA Therapeutics, by Type, Through 2028
• Table 40 : RoW Market for mRNA Therapeutics, by Type, Through 2028
• Table 41 : mRNA Patents: Top 10 Organizations
• Table 42 : Notable Patents for mRNA Therapeutics
• Table 43 : Some of the Notable Patents Related to mRNA Vaccines for Infectious Diseases
• Table 44 : Some of the Notable Patents Related to mRNA Vaccines for Cancer
• Table 45 : Notable Patents Focused on mRNA Delivery and Modification
• Table 46 : Recent M&A Deals on mRNA Therapeutics Company, 2006-2021
• Table 47 : Major Development of Company Profiles, 2021-2023
• Table 48 : BioNTech: Annual Revenue, 2021 and 2022
• Table 49 : BioNTech: News, 2021-2023
• Table 50 : BioNTech: ESG Developments, 2021
• Table 51 : BioNTech: Pipeline Products
• Table 52 : CureVac: Annual Revenue, 2021 and 2022
• Table 53 : CureVac: News, 2021-2023
• Table 54 : CureVac: Pipeline
• Table 55 : Merck: Annual Revenue, 2021 and 2022
• Table 56 : Merck: miRNA Product Portfolio
• Table 57 : Merck: Key Developments, Jan 2021-May 2023
• Table 58 : Moderna Inc.: Annual Revenue, 2021 and 2022
• Table 59 : Moderna Inc.: News, 2021-2023
• Table 60 : Moderna Inc.: Pipeline Products
• Table 61 : Nutcracker Therapeutics: Pipeline Products
• Table 62 : Strand Therapeutics: Pipeline Products
• Table 63 : Strand Therapeutics: News, 2021-2023

List of Figures

• Summary Figure : Global Market for mRNA Therapeutics, by Type, 2021-2028
• Figure 1 : Development Timeline: COVID-19 mRNA Vaccines
• Figure 2 : Reasons for Increasing Pandemics
• Figure 3 : Benefits of Vaccination
• Figure 4 : Investment in RNA Therapeutics 2011 to 2021
• Figure 5 : Global Prevalence of Breast Cancer Cases, by Region/Country, 2015-2025
• Figure 6 : Global Cancer-Related Deaths, by Cancer Type, 2000-2030
• Figure 7 : Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
• Figure 8 : Case Fatality Rate Share, Global Viral Outbreaks, 2020
• Figure 9 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
• Figure 10 : Global Prevalence of Angina Pectoris and Stroke (Survivors), 2004-2030
• Figure 11 : Global Prevalence of CHF and Stroke, 2004-2030
• Figure 12 : Trends in Obesity Composition of the Global Population, 2012-2025
• Figure 13 : Obesity and Severe Obesity vs. General Population in the U.S., 2018 and 2025
• Figure 14 : Global Distribution of Diabetes, by Type
• Figure 15 : Global Prevalence of Diabetes, by Type, 2018 and 2040
• Figure 16 : Global Prevalence of Key Symptomatic Musculoskeletal Disorders, 2012-2025
• Figure 17 : Global Deaths, by Type of Musculoskeletal Disorder, 2000-2030
• Figure 18 : Global Distribution of Mortality, by Chronic Disease Type, 2019
• Figure 19 : Global Distribution of DALYs, by Chronic Disease Type, 2019
• Figure 20 : Estimated World Population and Annual Growth, by Age Group, 2000-2030
• Figure 21 : Total Global Population, by Select Country/Region, 2000-2030
• Figure 22 : U.S. Population Estimates and Projections, by Age Group, 2000-2030
• Figure 23 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
• Figure 24 : European Population Estimates and Projections, by Age Group, 2000-2030
• Figure 25 : Japanese Population Estimates and Projections, by Age Group, 2000-2030
• Figure 26 : Distribution of Clinical Trials on mRNA Vaccines, by Disease Indication, 2023
• Figure 27 : Distribution of mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023
• Figure 28 : Distribution of mRNA Vaccine Candidates in Clinical Trials, by Mode of Administration, 2023
• Figure 29 : Clinical Trials on mRNA Therapeutics, Based on Recruiting Status, January 2020 to October 2023
• Figure 30 : Share of Clinical Trials on mRNA Therapeutics, With or Without Results, January 2020 to October 2023
• Figure 31 : Clinical Trials on mRNA Therapeutics, Based on Age Group, January 2020 to October 2023
• Figure 32 : Share of Clinical Trials on mRNA Therapeutics, Based on Gender, January 2020 to October 2023
• Figure 33 : Share of Clinical Trials on mRNA Therapeutics, by Trial Phase, January 2020 to October 2023
• Figure 34 : Share of Clinical Trials on mRNA Therapeutics, by Type of Funder, January 2020 to October 2023
• Figure 35 : Share of Clinical Trials on mRNA Therapeutics, by Enrollment Number, January 2020 to October 2023
• Figure 36 : Share of Clinical Trials on mRNA Therapeutics, by Interventional Mode, January 2020 to October 2023
• Figure 37 : Share of Clinical Trials on mRNA Therapeutics, by Type, January 2020 to October 2023
• Figure 38 : Global Market for mRNA Therapeutics, 2021-2028
• Figure 39 : Innovations in mRNA Therapeutics
• Figure 40 : mRNA Based Patent Publications, 2019-2021
• Figure 41 : Patents on mRNA Therapeutics, 2010-2021
• Figure 42 : Share of Patents on mRNA Therapeutics, by Patent Classification, 2010 to 2021
• Figure 43 : Funding in the mRNA Market, by Various Sources, 2021-2023
• Figure 44 : Top Three Companies: mRNA Vaccines and Therapeutics
• Figure 45 : Share of Key Growth Strategies of Major Companies, 2021-2023
• Figure 46 : BioNTech: Annual Revenue, 2021 and 2022
• Figure 47 : CureVac: Annual Revenue, 2020 and 2021
• Figure 48 : Merck: Annual Revenue, 2021 and 2022
• Figure 49 : Merck: Market Share, by Business Segment, 2022
• Figure 50 : Merck: Revenue Share, by Region, 2022
• Figure 51 : Moderna Inc.: Annual Revenue, 2021 and 2022
• Figure 52 : Moderna Inc.: Revenue Share, by Segment, 2022